Antidiuretic Hormone Receptor Antagonists
"Antidiuretic Hormone Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous compounds and drugs that inhibit or block the activity of ANTIDUIRETIC HORMONE RECEPTORS.
| Descriptor ID |
D065092
|
| MeSH Number(s) |
D27.505.519.174 D27.505.696.560.311
|
| Concept/Terms |
Antidiuretic Hormone Receptor Antagonists- Antidiuretic Hormone Receptor Antagonists
- Vasopressin Antagonists
- Antagonists, Vasopressin
- Vasopressin Receptor Antagonists
- Antagonists, Vasopressin Receptor
- Receptor Antagonists, Vasopressin
- Antidiuretic Hormone Antagonists
- Antagonists, Antidiuretic Hormone
- Hormone Antagonists, Antidiuretic
|
Below are MeSH descriptors whose meaning is more general than "Antidiuretic Hormone Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Antidiuretic Hormone Receptor Antagonists".
This graph shows the total number of publications written about "Antidiuretic Hormone Receptor Antagonists" by people in this website by year, and whether "Antidiuretic Hormone Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 1 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 4 | 0 | 4 |
| 2017 | 2 | 1 | 3 |
| 2018 | 2 | 1 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antidiuretic Hormone Receptor Antagonists" by people in Profiles.
-
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2020 12 31; 16(1):48-58.
-
Short-Term Efficacy and Safety of Tolvaptan in Patients with Left Ventricular Assist Devices. ASAIO J. 2020 03; 66(3):253-257.
-
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 2019 07; 96(1):159-169.
-
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol. 2018 10; 29(10):2458-2470.
-
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrol Dial Transplant. 2018 04 01; 33(4):645-652.
-
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2018 03 01; 33(3):477-489.
-
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2017 11 16; 377(20):1930-1942.
-
Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment. Am J Obstet Gynecol. 2018 04; 218(4):390-400.
-
Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2017 Jun 01; 32(6):969-975.
-
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. J Am Soc Nephrol. 2017 May; 28(5):1592-1602.